vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and EXPRO GROUP HOLDINGS N.V. (XPRO). Click either name above to swap in a different company.
EXPRO GROUP HOLDINGS N.V. is the larger business by last-quarter revenue ($382.1M vs $247.1M, roughly 1.5× ANI PHARMACEUTICALS INC). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs 1.5%, a 9.6% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs -12.5%). ANI PHARMACEUTICALS INC produced more free cash flow last quarter ($29.1M vs $23.2M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs -0.2%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Expro is an energy services provider headquartered in Houston, Texas, United States.
ANIP vs XPRO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $382.1M |
| Net Profit | $27.5M | $5.8M |
| Gross Margin | — | — |
| Operating Margin | 14.1% | 3.1% |
| Net Margin | 11.1% | 1.5% |
| Revenue YoY | 29.6% | -12.5% |
| Net Profit YoY | 367.5% | -74.9% |
| EPS (diluted) | $1.14 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $382.1M | ||
| Q3 25 | $227.8M | $411.4M | ||
| Q2 25 | $211.4M | $422.7M | ||
| Q1 25 | $197.1M | $390.9M | ||
| Q4 24 | $190.6M | $436.8M | ||
| Q3 24 | $148.3M | $422.8M | ||
| Q2 24 | $138.0M | $469.6M | ||
| Q1 24 | $137.4M | $383.5M |
| Q4 25 | $27.5M | $5.8M | ||
| Q3 25 | $26.6M | $14.0M | ||
| Q2 25 | $8.5M | $18.0M | ||
| Q1 25 | $15.7M | $13.9M | ||
| Q4 24 | $-10.3M | $23.0M | ||
| Q3 24 | $-24.2M | $16.3M | ||
| Q2 24 | $-2.3M | $15.3M | ||
| Q1 24 | $18.2M | $-2.7M |
| Q4 25 | 14.1% | 3.1% | ||
| Q3 25 | 15.9% | 6.4% | ||
| Q2 25 | 6.6% | 7.7% | ||
| Q1 25 | 13.3% | 2.6% | ||
| Q4 24 | -2.3% | 7.3% | ||
| Q3 24 | -13.8% | 6.2% | ||
| Q2 24 | 3.7% | 5.9% | ||
| Q1 24 | 14.8% | 2.2% |
| Q4 25 | 11.1% | 1.5% | ||
| Q3 25 | 11.7% | 3.4% | ||
| Q2 25 | 4.0% | 4.3% | ||
| Q1 25 | 8.0% | 3.6% | ||
| Q4 24 | -5.4% | 5.3% | ||
| Q3 24 | -16.3% | 3.8% | ||
| Q2 24 | -1.7% | 3.3% | ||
| Q1 24 | 13.2% | -0.7% |
| Q4 25 | $1.14 | $0.05 | ||
| Q3 25 | $1.13 | $0.12 | ||
| Q2 25 | $0.36 | $0.16 | ||
| Q1 25 | $0.69 | $0.12 | ||
| Q4 24 | $-0.45 | $0.20 | ||
| Q3 24 | $-1.27 | $0.14 | ||
| Q2 24 | $-0.14 | $0.13 | ||
| Q1 24 | $0.82 | $-0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $196.1M |
| Total DebtLower is stronger | — | $79.1M |
| Stockholders' EquityBook value | $540.7M | $1.5B |
| Total Assets | $1.4B | $2.3B |
| Debt / EquityLower = less leverage | — | 0.05× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $196.1M | ||
| Q3 25 | $262.6M | $197.9M | ||
| Q2 25 | $217.8M | $206.8M | ||
| Q1 25 | $149.8M | $179.3M | ||
| Q4 24 | $144.9M | $183.0M | ||
| Q3 24 | $145.0M | $165.7M | ||
| Q2 24 | $240.1M | $133.5M | ||
| Q1 24 | $228.6M | $163.2M |
| Q4 25 | — | $79.1M | ||
| Q3 25 | — | $99.1M | ||
| Q2 25 | — | $121.1M | ||
| Q1 25 | — | $121.1M | ||
| Q4 24 | — | $121.1M | ||
| Q3 24 | — | $121.1M | ||
| Q2 24 | — | $121.1M | ||
| Q1 24 | — | $40.0M |
| Q4 25 | $540.7M | $1.5B | ||
| Q3 25 | $505.8M | $1.5B | ||
| Q2 25 | $436.8M | $1.5B | ||
| Q1 25 | $418.6M | $1.5B | ||
| Q4 24 | $403.7M | $1.5B | ||
| Q3 24 | $405.9M | $1.5B | ||
| Q2 24 | $455.8M | $1.5B | ||
| Q1 24 | $452.0M | $1.3B |
| Q4 25 | $1.4B | $2.3B | ||
| Q3 25 | $1.4B | $2.3B | ||
| Q2 25 | $1.3B | $2.3B | ||
| Q1 25 | $1.3B | $2.3B | ||
| Q4 24 | $1.3B | $2.3B | ||
| Q3 24 | $1.3B | $2.3B | ||
| Q2 24 | $920.8M | $2.3B | ||
| Q1 24 | $914.5M | $2.0B |
| Q4 25 | — | 0.05× | ||
| Q3 25 | — | 0.07× | ||
| Q2 25 | — | 0.08× | ||
| Q1 25 | — | 0.08× | ||
| Q4 24 | — | 0.08× | ||
| Q3 24 | — | 0.08× | ||
| Q2 24 | — | 0.08× | ||
| Q1 24 | — | 0.03× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $57.1M |
| Free Cash FlowOCF − Capex | $29.1M | $23.2M |
| FCF MarginFCF / Revenue | 11.8% | 6.1% |
| Capex IntensityCapex / Revenue | 0.5% | 8.9% |
| Cash ConversionOCF / Net Profit | 1.10× | 9.89× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $97.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $57.1M | ||
| Q3 25 | $44.1M | $63.2M | ||
| Q2 25 | $75.8M | $48.4M | ||
| Q1 25 | $35.0M | $41.5M | ||
| Q4 24 | $15.9M | $97.4M | ||
| Q3 24 | $12.5M | $55.3M | ||
| Q2 24 | $17.4M | $-13.2M | ||
| Q1 24 | $18.3M | $29.9M |
| Q4 25 | $29.1M | $23.2M | ||
| Q3 25 | $38.0M | $39.0M | ||
| Q2 25 | $71.8M | $27.2M | ||
| Q1 25 | $32.5M | $8.4M | ||
| Q4 24 | $13.5M | $53.0M | ||
| Q3 24 | $7.7M | $23.3M | ||
| Q2 24 | $13.0M | $-49.5M | ||
| Q1 24 | $13.7M | $-801.0K |
| Q4 25 | 11.8% | 6.1% | ||
| Q3 25 | 16.7% | 9.5% | ||
| Q2 25 | 34.0% | 6.4% | ||
| Q1 25 | 16.5% | 2.1% | ||
| Q4 24 | 7.1% | 12.1% | ||
| Q3 24 | 5.2% | 5.5% | ||
| Q2 24 | 9.4% | -10.5% | ||
| Q1 24 | 10.0% | -0.2% |
| Q4 25 | 0.5% | 8.9% | ||
| Q3 25 | 2.7% | 5.9% | ||
| Q2 25 | 1.9% | 5.0% | ||
| Q1 25 | 1.3% | 8.5% | ||
| Q4 24 | 1.3% | 10.2% | ||
| Q3 24 | 3.2% | 7.6% | ||
| Q2 24 | 3.2% | 7.7% | ||
| Q1 24 | 3.3% | 8.0% |
| Q4 25 | 1.10× | 9.89× | ||
| Q3 25 | 1.66× | 4.52× | ||
| Q2 25 | 8.87× | 2.69× | ||
| Q1 25 | 2.23× | 2.98× | ||
| Q4 24 | — | 4.23× | ||
| Q3 24 | — | 3.40× | ||
| Q2 24 | — | -0.86× | ||
| Q1 24 | 1.00× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
XPRO
| NLA | $130.3M | 34% |
| ESSA | $116.3M | 30% |
| MENA | $93.0M | 24% |
| Other | $42.5M | 11% |
